Eyes on Korean Data: Lipid Management in Korean DM Patients
|
|
- Avice Chandler
- 5 years ago
- Views:
Transcription
1 Eyes on Korean Data: Lipid Management in Korean DM Patients ICDM Luncheon Symposium Sung Rae Kim MD PhD Division of Endocrinology and Metabolism The Catholic University of Korea
2 Causes of Death in People with Diabetes Ischemic Heart Disease Other Heart Disease Diabetes Cancer Stroke Infection Other Geiss LS, et al. In: Diabetes in America, 2nd ed Bethesda, MD: NIH; 1995.
3 Clinical Guidelines for Diabetes UK Prospective Diabetes Study (UKPDS): Order of importance for predicting CHD Variable P value 1. LDL-C < HDL-C HbA 1c Systolic BP Smoking Baseline epidemiologic data from 2,693 T2D patients using stepwise multivariate Cox models Modified from Turner RC, et al. BMJ 1998;316:823-28
4 Clinical Guidelines for Diabetes Joint European Task Force Diabetic patients have much higher total CVD risk than comparable nondiabetics Treatment goals for BP and lipids in diabetic patients should be more ambitious ADA - Statin therapy should be added to lifestyle therapy, regardless of baseline lipid levels, for diabetic patients: with overt CVD (A) without CVD who are over the age of 40 and have one or more other CVD risk factors. (A)
5 NCEP ATP III Risk Category LDL-C Goal Initiate TLC High risk: CHD or CHD risk equivalents (10-year risk >20%) Moderately high risk: 2+ risk factors (10-year risk 10% to 20%) Moderate risk: 2+ risk factors (10 year risk <10%) Lower risk: 0-1 risk factor Clinical Guidelines for Diabetes <100 mg/dl (optional goal: <70 mg/dl) 100 mg/dl Consider Drug Therapy 100 mg/dl (<100 mg/dl: consider drug options) <130 mg/dl 130 mg/dl 130 mg/dl ( mg/dl: consider drug options) <130 mg/dl 130 mg/dl 160 mg/dl <160 mg/dl 160 mg/dl 190 mg/dl ( mg/dl: LDLlowering drug optional) Grundy, S. et al., Circulation 2004;110:
6 Lipid Goals in Patients With Diabetes ADA & ACC Statement (Consensus statement from the ADA and the ACC foundation) Goals LDL cholesterol (mg/dl) Non-HDL cholesterol (mg/dl) ApoB (mg/dl) Highest-risk patients, including those with 1) known CVD or 2) diabetes plus one or more additional major CVD risk factor <70 <100 <80 High-risk patients, including those with 1) no diabetes or known clinical CVD but two or more additional major CVD risk factors or 2) diabetes but no other major CVD risk factors <100 <130 <90 Other major risk factors (beyond dyslipoproteinemia) include smoking, hypertension, and family history of premature CAD ADA. Diabetes Care 2008;31:
7 Clinical Guidelines for Diabetes 2011 ESC/EAS Guideline Risk category LDL-C goal Evidence Very High CV Risk: Known CVD, T2DM or T1DM with microalbuminuria, CKD, SCORE level: 10% ~70 mg/dl and/or 50% reduction in level when target level cannot be reached Class I, A High CV Risk: Very high levels of individual risk factors, SCORE level: 5% and <10% Moderate Risk: SCORE level: 5% and <10% ~100 mg/dl Class IIa, A ~115 mg/dl Class IIa, C
8 Percent (%) Prevalence of Hyper-LDL-cholesterolemia according to diabetic status in Korea 50 Nondiabetes Diabetes % % 24.4% 25.8% % 7.5% 7.5% 13.4% 8.4% 18.2% 10.0% 12.0% 11.9% 12.9% Year 2011 KNHANES
9 Awareness rate in Korea Awareness rate All subjects Total 6.1 (0.4) 8.8 (1.0) 11.2 (0.6) 11.9 (0.6) 13.7 (0.7) Men 7.3 (0.7) 10.6 (1.6) 11.5 (1.0) 11.4 (0.8) 12.7 (1.1) Women 5.2 (0.5) 7.3 (0.9) 10.9 (0.7) 12.3 (0.8) 14.6 (0.9) Nondiabetic subjects Total 5.3 (0.4) 7.7 (1.0) 10.1 (0.6) 10.4 (0.6) 11.0 (0.7) Men 6.6 (0.7) 9.5 (1.6) 11.2 (1.1) 9.9 (0.9) 10.4 (1.1) Women 4.5 (0.5) 6.1 (1.0) 9.1 (0.8) 10.8 (0.8) 11.5 (0.8) Diabetic subjects Total 12.9 (1.8) 18.4 (3.4) 19.2 (1.8) 23.4 (2.2) 34.6 (3.0) Men 12.2 (2.5) 17.5 (5.6) 14.1 (2.5) 22.3 (3.1) 29.7 (3.8) Women 13.6 (2.7) 19.6 (4.4) 23.9 (2.6) 24.5 (2.8) 39.8 (3.9) 2011 KNHANES
10 Treatment rate in Korea Treatment rate All subjects Total 1.9 (0.2) 3.0 (0.4) 3.8 (0.3) 5.2 (0.4) 7.4 (0.6) Men 1.9 (0.4) 3.2 (0.7) 3.0 (0.4) 4.4 (0.5) 6.3 (0.8) Women 1.9 (0.3) 2.8 (0.5) 4.6 (0.4) 6.0 (0.6) 8.4 (0.8) Nondiabetic subjects Total 1.3 (0.2) 2.3 (0.4) 3.0 (0.3) 4.1 (0.4) 5.3 (0.5) Men 1.6 (0.4) 2.5 (0.7) 2.4 (0.5) 3.0 (0.5) 4.5 (0.7) Women 1.2 (0.2) 2.0 (0.6) 3.5 (0.4) 5.0 (0.5) 6.0 (0.6) Diabetic subjects Total 7.3 (1.4) 9.5 (2.3) 10.0 (1.4) 14.4 (1.7) 23.6 (2.8) Men 4.5 (1.5) 8.1 (3.0) 7.0 (1.7) 14.5 (2.6) 16.0 (0.6) Women 10.1 (2.4) 11.2 (3.6) 12.9 (2.0) 14.4 (2.3) 28.2 (3.9) 2011 KNHANES
11 Control rate in Korea Control rate Diabetic subjects (LDL-C goal : LDL-C <100 mg/dl) Total 41.9 (11.9) 70.4 (11.8) 45.1 (7.4) 62.6 (6.5) 62.6 (5.6) Men 62.5 (20.1) 81.8 (17.4) 63.2 (12.6) 70.7 (9.7) 64.3 (9.8) Women 33.6 (13.5) 61.1 (15.3) 36.7 (8.6) 55.1 (8.9) 61.6 (7.3) Diabetic subjects with 1 or more risk factor of CAD (LDL-C goal : LDL-C <70 mg/dl) Total 8.6 (5.6) 17.1 (9.1) 14.8 (5.3) 23.6 (5.3) 22.2 (4.8) Men 19.6 (17.8) (12.2) 27.4 (7.8) 30.0 (10.1) Women 4.3 (4.2) 31.2 (15.0) 9.9 (4.7) 19.8 (6.9) 17.2 (5.4) 2011KNHANES
12
13 Enrollment of diabetic Pts with hypercholesterolemia Patients who visited clinic between May I and Aug 31, 2010 Patients with minimum 3 months pre-index eligibility(n=2,691) Exclude patients without laboratory results at baseline and final visit(n=2,591) Exclude patients missing data to calculate Framingham 10-yr risk(n=2,093) Diabetes Metab J. 2011; 35:
14 Target attainment rate (%) Low LDL-C Goal Attainment Rate in Korean Patients with Diabetes Baseline Final Visit Overall Highest-Risk pts. High-Risk pts. Multi-center, retrospective, non-interventional, observational study, total 2,591 enrolled patients Diabetes Metab J. 2011; 35:
15 LDL-C goal attainment rate (%) Gap between Physician s Perception and Guidelines At Goal Doctor's Perception Guideline LDL-C goal attainment and actual results according to the 2008 ADA/ACC guidelines Multi-center, retrospective, non-interventional, observational study, total 2,591 enrolled patients Diabetes Metab J. 2011; 35:
16 Physician Treatment Strategies to achieve Target Goals (By physicians answers to a survey) (%) 80 Base : n= Adding drugs Change drugs Increasing Increasing Maintain dosage dosage & adding drugs current therapy Diabetes Metab J. 2011; 35:
17 Physician Treatment Strategies to achieve Target Goals (By chart review) (%) 70 Base : n=2, Up titration Down titration Drug change No change No drug Multi-center, retrospective, non-interventional, observational study, total 2,591 enrolled patients Diabetes Metab J. 2011; 35:
18 AMADEUS Study A Multicenter, eight weeks treatment, single step titration, open label with Atorvastatin starting dose 10 mg, 20 mg, 40 mg assessing the percentage of Korean Diabetes Mellitus Dyslipidemic Patients achieving LDL cholesterol target Study
19 Deus : God, Amor : love the most AMADEUS : God love the most Amadeus Mozart (Mozart was a great musician of his time) J Diabetes Investig. 2013;4:
20 Background NCEP and ATP III guideline Treating cardiovascular risk factors in patients with type 2 diabetes as aggressively as non-diabetic patients in high risk CHD category Therapy for diabetic dyslipidemia is directed to first lowering serum LDL cholesterol levels (< 100 mg/dl) by statin in patients with type 2 diabetes If serum triglyceride levels are >200 mg/dl, the non HDL cholesterol goal becomes a secondary target Evidence for a decrease in cardiovascular events among patients with type 2 diabetes has accumulated from several major statin trials CARDS PROVE-IT JUPITER
21 Background Despite multiple guidelines and supporting data, overall achieving LDL cholesterol target goals falls far below expectations in type 2 diabetes Main factors for this failure may be associated with selection of an inappropriate starting dose and difficulties in dose up-titration to reach the target goal More recently, several clinical trials have shown that patient-tailored statin therapy according to individual s CHD risk or their baseline LDL cholesterol value allows for a larger number of patients to achieve target LDL cholesterol NASDAC ATGOAL ACTFAST
22 Background However, few studies previously have focused on the effectiveness of an individualizing starting dose according to baseline LDL cholesterol levels to achieve target goals in patients with type 2 diabetes who were free from CHD Furthermore, little data are available about the efficacy of these flexible starting doses on atherogenic lipid profiles and low grade inflammation in patients with type 2 diabetes
23 Methods Multicenter(18), single-step titration(lipitor 10 mg, 20 mg, 40 mg) Open-label study Pts: Age 18-80, Type 2 DM Pts 440(HbA 1c : below 10%, ADA criteria ) No CAD risk Pt, LDL cholesterol target is below 100 mg/dl LDL-C baseline ITT (n=440) Lipitor 40 mg (n=74) 80 mg Complete n=65 100~129 mg/dl: 10mg 130~159 mg/dl: 20mg 160~220 mg/dl: 40mg Screening Lipitor 20 mg (n=181) Lipitor 10 mg (n=185) 4wk 40 mg 20 mg 8wk Complete n=161 Complete n=177 Visit 1 Visit 2 Visit 3 J Diabetes Investig. 2013;4: ADA: American Diabetes Association, ITT : intention to-treat
24 Result The proportion of patients achieving LDL-C target J Diabetes Investig. 2013;4: ITT : intention to-treat, PP: per-protocol
25 Result Achieving LDL-C target with the initial dose 10 mg (n=185) 10mg (n=172) Dose of change (n=13) ( ) ( ) 10 mg (n=177) 10mg (n=168) 20mg (n=9) ( ) ( ) 20 mg (n=181) 20mg (n=160) Dose of change (n=21) ( ) ( ) 20 mg (n=161) 20mg (n=153) 40mg (n=8) ( ) 100 ( ) 40 mg (n=74) 40mg (n=62) Dose of change (n=12) ( ) ( ) 40 mg (n=65) 40mg (n=60) 80mg (n=5) ( ) 60 ( ) All dose Initial dose Dose of change ( ) ( ) All dose Initial dose Up-titration ( ) ( ) J Diabetes Investig. 2013;4: ITT : intention to-treat, PP: per-protocol
26 Result Change of lipid profile Variables 10 mg (n=185) 20 mg (n=181) 40 mg (n=74) [Unit: mg/dl Total cholesterol (mg/dl) Baseline (mean S.D.) Week 8 (mean S.D.) Change (95% CI) ± ± ( )* ± ± ( )* ± ± ( )* Triglyceride (mg/dl) Baseline (mean S.D.) Week 8 (mean S.D.) Change (95% CI) ± ± ( )* ± ± ( )* ± ± ( )* HDL cholesterol (mg/dl) Baseline (mean S.D.) Week 8 (mean S.D.) Change (95% CI) ± ± ( )* ± ± ( ) ± ± ( ) LDL cholesterol (mg/dl) Baseline (mean S.D.) Week 8 (mean S.D.) Change (95% CI) TC/HDL ratio(mean S.D.) Baseline (mean S.D.) Week 8 (mean S.D.) Change (95% CI) LDL/HDL ratio Baseline (mean S.D.) Week 8 (mean S.D.) Change (95% CI) Non-HDL (mg/dl) Baseline (mean S.D.) Week 8 (mean S.D.) Change (95% CI) J Diabetes Investig. 2013;4: TC: total cholesterol, LDL-C: low density lipoprotein cholesterol, HDL-C: high density lipoprotein ± ± ( )* 4.32 ± ± ( )* 2.64 ± ± ( )* ± ± ( )* ± ± ( )* 4.81 ± ± ( )* 3.14 ± ± ( )* ± ± ( )* ± ± ( )* 41.69% 48.19% 53.43% 5.47 ± ± ( )* 3.86 ± ± ( )* ± ± ( )*
27 Result Change of sd-ldl cholesterol J Diabetes Investig. 2013;4: Sd-LDL: small,dense LDL
28 Result Change of hscrp hscrp <3 mg/l hscrp 3 mg/l J Diabetes Investig. 2013;4: hscrp: high sensitive C-reactive protein
29 Result Change of Adiponectin Adiponectin J Diabetes Investig. 2013;4:
30 Result -Adverse events J Diabetes Investig. 2013;4:
31 Summary Overall, 93.8% of patients achieved their LDL cholesterol target at week 8 (94%, 97% and 85% for the 10, 20 and 40 mg doses, respectively) Among patients who achieved target goal, over 94.5% achieved their LDL cholesterol target with the initial dose (95%, 97% and 87% for the 10, 20 and 40 mg doses, respectively) There were significant reductions in TC, TC/HDL cholesterol ratio, LDL/HDL cholesterol ratio, triglycerides and non-hdl cholesterol compared to baseline at week 8 for all doses Especially, reductions in small dense LDL cholesterol levels were significant after 8 weeks with all doses, and this finding was more prominent in higher doses Significant increases in adiponectin between week 4 and 8 were also observed with all doses Atorvastatin was well tolerated at all doses
32 Thank you for your attention!!
Review of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationLatest Guidelines for Lipid Management
Latest Guidelines for Lipid Management Goals Recognize the differences between different guidelines Understand the effective strategies to tailor lipid lowering therapies based on evidence and guideline
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationTailored Statin Treatment for Type 2 Diabetes. Han, Ki Hoon Asan Medical Center University of Ulsan
Tailored Statin Treatment for Type 2 Diabetes Han, Ki Hoon Asan Medical Center University of Ulsan 1 Cardiovascular disease ; No1. death (2001) respiratory tract infection Other NCD S HIV/AIDS deaths during
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationHow to Reduce CVD Complications in Diabetes?
How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationHDL-C. J Jpn Coll Angiol, 2008, 48: NIPPON DATA80, MEGA study, JELIS, dyslipidemia, risk assessment chart
Online publication March 25, 2009 48 6 2007 2007 HDL-C LDL-C HDL-C J Jpn Coll Angiol, 2008, 48: 463 470 NIPPON DATA80, MEGA study, JELIS, dyslipidemia, risk assessment chart 1987 NIPPON DATA80 Iso 10 MRFIT
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationYoung high risk patients the role of statins Dr. Mohamed Jeilan
Young high risk patients the role of statins Dr. Mohamed Jeilan KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures
More informationNew Guidelines in Dyslipidemia Management
The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital 1. Importance of Lowering LDL-Cholesterol in Diabetes Patients & Lipid Guidelines Prevalence of dyslipidemia in Korea Prevalence
More informationLipid Management 2013 Statin Benefit Groups
Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More informationConsiderations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction
Considerations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction Pamela B. Morris, MD, FACC, FAHA, FASCP, FNLA Chair, ACC Prevention of Cardiovascular Disease Council The Medical
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationNew Guidelines in Dyslipidemia Management
The Third IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2017 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More informationLDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More informationCVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic
CVD Risk Assessment Michal Vrablík Charles University, Prague Czech Republic What is Risk? A cumulative probability of an event, usually expressed as percentage e.g.: 5 CV events in 00 pts = 5% risk This
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationStatins for Cardiovascular Disease Prevention in Women: Review of the Evidence
Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence Karen E. Aspry, M.D., M.S., ABCL, FACC Assistant Professor of Medicine (Clinical) Alpert Medical School of Brown University
More informationHyperlipidemia. Intern Immersion Block 2015
Hyperlipidemia Intern Immersion Block 2015 Christopher Wong, MD Division of General Internal Medicine University of Washington cjwong@u.washington.edu Welcome! Disclosures: royalties from book sales (not
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationDyslipidemia and the Use of Statins. Troy L Randle, DO, FACC, FACOI
Dyslipidemia and the Use of Statins Troy L Randle, DO, FACC, FACOI Objective: Identify CV risk. Determine what dyslipidemia (dyslipoproteinemia) is Decrease CV risk and optimize lipid levels for your
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationTreatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center
Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationAssessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution
CLINICAL Viewpoint Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients Copyright Not for Sale or Commercial Distribution By Ruth McPherson, MD, PhD, FRCPC Unauthorised
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationLearning Objectives. Patient Case
Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Learning Objectives Identify the 4 patient populations
More informationDiabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology
Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the
More informationLipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute
Lipid Management 2018 C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Disclosures No Financial Disclosures Disclosures I am an Interventional Cardiologist I put STENTS in for
More informationFelix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study
Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study Conflict of interest disclosure None Committee of Scientific Affairs Committee
More informationHyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH
Mark slides Hyperlipidemia: Lowering the Bar on the Lipid Limbo Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Hyperlipidemia is a common problem Nearly 50% of men in the
More informationNew Lipid Lowering Agents (PCSK9 Inhibitors, Bempedoic Acid, Apabetalone) in the Elderly? The State of the Recent Knowledge Prof.
New Lipid Lowering Agents (PCSK9 Inhibitors, Bempedoic Acid, Apabetalone) in the Elderly? The State of the Recent Knowledge Prof. Maciej Banach Łódź, PL According to : Central Intelligence Agency". Retrieved
More informationComprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium
Comprehensive Treatment for Dyslipidemias Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium Primary Prevention 41 y/o healthy male No Medications Normal BP, Glucose and BMI Social History:
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationThe promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease
The promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease Steve Smith, Group Director Scientific Affairs, Diabetes & Metabolism GlaxoSmithKline R & D
More informationCopyright 2017 by Sea Courses Inc.
Diabetes and Lipids Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or
More informationAccelerated atherosclerosis begins years prior to the diagnosis of diabetes
Joslin Diabetes Forum 211: Optimizing Care for the Practicing Clinician Risk for atherosclerosis is 2 4 times greater in patients with diabetes CVD accounts for 65% of diabetic mortality >5% of patients
More informationUpdate On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?
Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID? Karen Aspry, MD, MS, ABCL, FACC Assistant Clinical Professor of Medicine Warren Alpert Medical School of Brown
More informationHighlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM
Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM OSHP 2014 Annual Meeting Oklahoma City, OK April 4, 2014 1 Objectives
More informationThe TNT Trial Is It Time to Shift Our Goals in Clinical
The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia
More informationDiabetic Dyslipidemia
Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals
More informationDavid Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon
David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon I have no actual or potential conflicts of interest in relation to this program or presentation. Raphael School of Athens, 1509-1511 Apply
More informationTreatment to reduce cardiovascular risk: multifactorial management
Treatment to reduce cardiovascular risk: multifactorial management Matteo Anselmino, MD PhD Assistant Professor San Giovanni Battista Hospital Division of Cardiology, Department of Internal Medicine University
More informationMetabolic Syndrome. Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah
Metabolic Syndrome Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah Objectives Be able to outline the pathophysiology of the metabolic syndrome Be able to list diagnostic criteria for
More informationPharmaceutical Help to Control Cholesterol
Pharmaceutical Help to Control Cholesterol Catherine E. Cooke, PharmD, BCPS, PAHM President, PosiHealth, Inc. Clinical Associate Professor, Univ. of Maryland This program has been brought to you by PharmCon
More informationCVD Risk Assessment. Lipid Management in Women: Lessons Learned. Conflict of Interest Disclosure
Lipid Management in Women: Lessons Learned Conflict of Interest Disclosure Emma A. Meagher, MD has no conflicts to disclose Emma A. Meagher, MD Associate Professor, Medicine and Pharmacology University
More informationUpdate on CVD and Microvascular Complications in T2D
Update on CVD and Microvascular Complications in T2D Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationSCIENTIFIC STUDY REPORT
PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established
More informationPrevention of Heart Disease: The New Guidelines
Prevention of Heart Disease: The New Guidelines Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California San Francisco May 18 th 2015
More information5/28/2010. Pre Test Question
Myth of Metabolic Syndrome? C. W. Spellman, DO, PhD Professor and Associate Dean Research Dir. Center Diabetes and Metabolic Disorders Department Internal Medicine, Div. Endocrinology Texas Tech University
More informationWelcome! Mark May 14, Sat!
Welcome! Mark May 14, Sat! Do We Have All Answers with Statins In Treating Patients with Hyperlipidemia? Kwang Kon Koh, MD, PhD, FACC, FAHA Cardiology, Gil Heart Center, Gachon Medical School, Incheon,
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More information1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationMacrovascular Management. What s next beyond standard treatment?
Macrovascular Management What s next beyond standard treatment? Are Lifestyle Modifications Still Relevant in Diabetic Patients? Diet Omega-6 and omega-3 fatty acids have been shown to improve CVD risk
More informationThe Latest Generation of Clinical
The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform
More informationGuidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AMERICAN COLLEGE OF ENDOCRINOLOGY Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease Writing Committee Chair: Paul S. Jellinger,
More informationLessons from Recent Atherosclerosis Trials
Lessons from Recent Atherosclerosis Trials Han, Ki Hoon MD PhD Asan Medical Center Seoul, Korea Change of concept Primary vs. secondary prevention Low risk vs. High risk High Risk CHD and equivalents CHD
More information2017 Cardiovascular Summit for Primary Care Thursday 30th & Friday 31st March Crowne Plaza, Dublin
2017 Cardiovascular Summit for Primary Care Thursday 30th & Friday 31st March 2017 - Crowne Plaza, Dublin 2016 ESC Guidelines on Cardiovascular Risk and elevated lipids Carlos Brotons Sardenya Primary
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationReview current guideline recommendations for lipid-lowering therapy
Breakout Session #3 New Paradigms in the Management of Dyslipidemia Review current guideline recommendations for lipid-lowering therapy Dr Meral KAYIKCIOGLU Ege University Medical School, Cardiology Dept,
More informationAn update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine
An update on lipidology and cardiovascular risk management Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine National and international lipid modification guidelines: A critical appraisal
More informationSlide 1. Slide 2. Slide 3. A Fork in the Road: Navigating Through New Terrain. Diabetes Standards of Care Then and Now
Slide 1 A Fork in the Road: Navigating Through New Terrain Carol Hatch Wysham, MD Clinical Associate Professor of Medicine University of Washington School of Medicine Section Head, Rockwood Center for
More informationDiabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018
Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018 Points to Ponder ASCVD is the leading cause of morbidity
More informationPitavastatin 4 mg vs. Pravastatin 40 mg in HIV Dyslipidemia: Post- Hoc Analysis of the INTREPID Trial Based on the Independent CHD Risk Factor for Age
Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV Dyslipidemia: Post- Hoc Analysis of the INTREPID Trial Based on the Independent CHD Risk Factor for Age Craig A. Sponseller, Masaya Tanahashi, Hideki Suganami,
More informationLow-density lipoprotein as the key factor in atherogenesis too high, too long, or both
Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Lluís Masana Vascular Medicine and Metabolism Unit. Sant Joan University Hospital. IISPV. CIBERDEM Rovira i Virgili
More informationESC/EAS GUIDELINES ON MANAGEMENT OF DYSLIPIDEMIAS IN CLINICAL PRACTICE
ESC/EAS GUIDELINES ON MANAGEMENT OF DYSLIPIDEMIAS IN CLINICAL PRACTICE Professor Željko Reiner, MD, PhD,FRCP(Lond), FESC Director, University Hospital Center Zagreb School of Medicine, University of Zagreb,
More informationWelcome and Introduction
Welcome and Introduction This presentation will: Define obesity, prediabetes, and diabetes Discuss the diagnoses and management of obesity, prediabetes, and diabetes Explain the early risk factors for
More informationPlacebo-Controlled Statin Trials
PREVENTION OF CHD WITH LIPID MANAGEMENT AND ASPIRIN: MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of
More informationSeung-Hwan Lee, M.D., Ph.D.
2015.10.16. ICDM, DMJ session Statin discontinuation after achieving a target low-density lipoprotein cholesterol level in type 2 diabetic patients without cardiovascular disease: a randomized controlled
More informationLipid Management: A Case-Based Approach. Overview. Simple Lipid Therapy Approach. Patients have lipid disorders of:
Lipid Management: A Case-Based Approach Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public
More informationHow to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
More informationPIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia
PIEDMONT ACCESS TO HEALTH SERVICES, INC. Policy Number: 01-09-021 SUBJECT: Guidelines for Screening and Management of Dyslipidemia EFFECTIVE DATE: 04/2008 REVIEWED/REVISED: 04/12/10, 03/17/2011, 4/10/2012,
More informationOn May 2001, the Third Adult
THE RISK OF DIABETES: CAN WE IMPACT CHD THROUGH THE ATP III CHOLESTEROL GUIDELINES? * Based on a presentation given by Steven M. Haffner, MD, MPH ABSTRACT Diabetes has been recognized among diabetologists
More informationDisclosures. Prevention of Heart Disease: The New Guidelines. Summary of Talk. Four guidelines. No relevant disclosures.
Disclosures Prevention of Heart Disease: The New Guidelines No relevant disclosures Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationDyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram
Dyslipidaemia Is there any new information? Dr. A.R.M. Saifuddin Ekram PhD,FACP,FCPS(Medicine) Professor(c.c.) & Head Department of Medicine Rajshahi Medical College Rajshahi-6000 New features of ATP III
More informationEnvironmental. Vascular / Tissue. Metabolics
Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood
More informationCardiovascular Risk Assessment: A Systematic Review of Guidelines.
Cardiovascular Risk Assessment: A Systematic Review of Guidelines. Khanji, MY; Bicalho, VVS; van Waardhuizen, CN; Ferket, BS; Petersen, SE; Hunink, MGM 2016 American College of Physicians This is a pre-copyedited,
More informationSTATIN UTILIZATION MANAGEMENT CRITERIA
STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationTen Year Risk for CVD Event by Systolic HTN and CVD Risk Factors (Where s Age?)
Prevention and Treatment of CVD in Older Patients with Diabetes and Pre Diabetes: Hypertension and Dyslipidemia ASP Workshop on Diabetes Mellitus and Cardiovascular Disease in Older Adults Pentagon City
More information2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice
2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice Nattawut Wongpraparut, MD, FACP, FACC, FSCAI Associate Professor of Medicine, Division of Cardiology, Department of Medicine
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia
Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,
More informationCorrelation of novel cardiac marker
Correlation of novel cardiac marker and mortality in EGAT population. Soluble ST2 hscrp Poh Chanyavanich, MD SukitYamwong, MD Piyamitr Sritara, MD Ramathibodi hospital Background hscrp - the most widely
More informationGUIDELINES FOR DYSLIPIDEMIA MANAGEMENT AND EDUCATION THROUGH NOVA SCOTIA DIABETES CENTRES
GUIDELINES FOR DYSLIPIDEMIA MANAGEMENT AND EDUCATION THROUGH NOVA SCOTIA DIABETES CENTRES Prepared by DCPNS Action Committee Dr. Lynne Harrigan Brenda Cook Peggy Dunbar Bev Harpell with the assistance
More informationGet a Statin or Not? Learning objectives. Presentation overview 4/3/2018. Treatment Strategies in Dyslipidemia Management
Get a Statin or Not? Treatment Strategies in Dyslipidemia Management Michelle Chu, PharmD, BCACP, CDE Assistant Professor of Clinical Pharmacy, USC School of Pharmacy Sahar Dagher, PharmD Virtual Care
More informationwell-targeted primary prevention of cardiovascular disease: an underused high-value intervention?
well-targeted primary prevention of cardiovascular disease: an underused high-value intervention? Rod Jackson University of Auckland, New Zealand October 2015 Lancet 1999; 353: 1547-57 Findings: Contribution
More informationPREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
1980 to 2000: Death rate fell from: 542.9 to 266.8 per 100K men 263.3 to 134.4 per 100K women 341,745 fewer deaths from CHD in 2000 Ford ES, NEJM, 2007 47% from CHD treatments, 44% from risk factor modification
More information